Patients with inflammatory bowel disease (IBD) may be at increased risk for pneumocystis jiroveci pneumonia (PCP). Our aims were (1) to determine the incidence and relative risk of PCP in IBD and (2) to describe medication exposures in patients with IBD with PCP.
We performed a retrospective cohort study and a case series using administrative data from IMS Health Inc, LifeLink Health Plan Claims Database. In the cohort, patients with IBD were matched to 4 individuals with no IBD claims. PCP risk was evaluated by incidence rate ratio and adjusted Cox proportional hazards modeling. The demographics and medication histories of the 38 cases of PCP in patients with IBD were extracted.
The cohort included 50,932 patients with Crohn’s disease, 56,403 patients with ulcerative colitis, and 1269 patients with unspecified IBD; matched to 434,416 individuals without IBD. The crude incidence of PCP was higher in the IBD cohort (10.6/100,000) than in the non-IBD cohort (3.0/100,000). In the adjusted analyses, PCP risk was higher in the IBD versus non-IBD cohort (hazard ratio, 2.96; 95% confidence interval, 1.75–4.29), with the greatest risk in Crohn’s disease compared with non-IBD (hazard ratio, 4.01; 95% confidence interval, 1.88–8.56). In the IBD case series of PCP cases (n = 38), the median age was 49 (interquartile range, 43–57). A total of 20 individuals (53%) were on corticosteroids alone or in combination with other immunosuppression.
Although the overall incidence of PCP is low, patients with IBD are at increased risk. Patients with IBD with PCP are predominantly on corticosteroids alone or in combination before PCP diagnosis.
Article first published online 8 March 2013
*Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
†Center for Gastrointestinal Biology and Disease, Chapel Hill, North Carolina
‡Section of Gastroenterology, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts
§Division of Gastroenterology and Hepatology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Reprints: Millie D. Long, MD, MPH, University of North Carolina at Chapel Hill, Campus Box 7080, Chapel Hill, NC 27599-7080 (e-mail: email@example.com).
Supported by a Career Development Award from the Crohn’s and Colitis Foundation of America (M.D.L.), NIH 1K08DK088957-01 (M.D.K.), and NIH P30 DK34987 (R.S.S.).
The authors have no relevant conflicts of interest to disclose.
The statements, findings, conclusions, views, and opinions contained and expressed in this article are based in part on data obtained under license from the following IMS Health Incorporated information service(s): IMS LifeLink Health Plan Claims Database (1997–2009), IMS Health Incorporated. All Rights Reserved. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IMS Health Incorporated or any of its affiliated or subsidiary entities.
Received July 13, 2012
Accepted July 13, 2012